title: Doubly Labeled Water Method and Accelerometer for the Measurement of Energy Expenditure in Human Immunodeficiency Virus-Infected Patients.
abstract: Several studies have reported increased resting energy expenditure (REE) in human immunodeficiency virus (HIV)-infected patients with HIV-associated lipodystrophy syndrome (HALS). However, limited data exist on the total energy expenditure (TEE). This study was aimed at evaluating the REE and TEE of HIV-infected patients with and without HALS by using the doubly labeled water (DLW) technique and the activity monitor based on accelerometry system (AM), and comparing the results obtained using both methods.
  
  
  
  Evaluated total of 45 HIV+ men undergoing antiretroviral therapy, including 18 LIPO- (without lipodystrophy) and 27 LIPO+ (with lipodystrophy) individuals were evaluated. Habitual physical activity patterns were measured by using the ActivPAL™ AM system, REE by indirect calorimetry, and TEE by DLW and AM.
  
  
  
  No significant differences were found between LIPO- and LIPO+ in REE (1,433 ± 196 vs. 1,510 ± 203 kcal), TEE-DLW (2,691 ± 856 vs. 2,618 ± 415 kcal) and TEE-AM (2,560 ± 458 vs. 2,594 ± 456 kcal), respectively. RQ was a predictor of REE in LIPO+. TEE estimated by the AM had a moderate correlation with DLW, but there was a wide variance in the intra-subject results.
  
  
  
  TEE is not increased in HIV-infected patients with HALS. AM should be used with caution for TEE evaluation during clinical practice.
authors.affiliation: Department of Internal Medicine, Ribeirao Preto Medical School, University of Sao Paulo, Ribeirão Preto, Brazil.
authors.forename: Mariana P
authors.initials: MP
authors.lastname: Guimarães
authors.forename: Eduardo
authors.initials: E
authors.lastname: Ferriolli
authors.forename: Karina
authors.initials: K
authors.lastname: Pfrimer
authors.forename: Anderson M
authors.initials: AM
authors.lastname: Navarro
mesh_terms: D061725:Accelerometry; D000328:Adult; D044966:Anti-Retroviral Agents / Q000627:therapeutic use*; D002153:Calorimetry, Indirect; D017666:Deuterium Oxide; D004734:Energy Metabolism; D015658:HIV Infections / Q000188:drug therapy / Q000378:metabolism; D039682:HIV-Associated Lipodystrophy Syndrome / Q000188:drug therapy / Q000378:metabolism*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011237:Predictive Value of Tests; D055815:Young Adult
chemical_list: D044966:Anti-Retroviral Agents; D017666:Deuterium Oxide